{
    "id": 31714,
    "fullName": "B2M V5Lfs*30",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "B2M V5Lfs*30 indicates a shift in the reading frame starting at amino acid 5 and terminating 30 residues downstream causing a premature truncation of the 119 amino acid B2m protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), V5Lfs*30 is predicted to lead to a loss of B2m protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 567,
        "geneSymbol": "B2M",
        "terms": [
            "B2M",
            "IMD43"
        ]
    },
    "variant": "V5Lfs*30",
    "createDate": "12/04/2019",
    "updateDate": "02/20/2020",
    "referenceTranscriptCoordinates": {
        "id": 185800,
        "transcript": "NM_004048",
        "gDna": "chr15:g.(44711559_44715460)",
        "cDna": "c.(13_105)",
        "protein": "p.V5Lfs*30",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19435,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19437,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19436,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34102,
            "profileName": "B2M V5Lfs*30",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34105,
            "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 185801,
            "transcript": "XM_005254549",
            "gDna": "chr15:g.(44711559_44715460)",
            "cDna": "c.(13_105)",
            "protein": "p.V5Lfs*30",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 185800,
            "transcript": "NM_004048",
            "gDna": "chr15:g.(44711559_44715460)",
            "cDna": "c.(13_105)",
            "protein": "p.V5Lfs*30",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}